![]() Packaging for the Brazilian version of NDV-HXP-S, ButanVac | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | viral vector or inactivated |
Clinical data | |
Trade names | ButanVac (Brazil) COVIVAC (Vietnam) HXP-GPOVac (Thailand) Patria (Mexico) |
Other names | ADAPTCOV |
Routes of administration | Intramuscular,[1] Intranasal |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
NDV-HXP-S (known as ButanVac[2][3] or ADAPTCOV[4] in Brazil, COVIVAC[5] in Vietnam, HXP-GPOVac[6] in Thailand, Patria[7] in Mexico) is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.[8][9]
The name NDV-HXP-S comes from the terms Newcastle disease virus, HexaPro, and spike protein.[8] The stabilization of the S protein of SARS-CoV-2 (HexaPro) was achieved by Jason McLellan from the University of Texas at Austin.[10]
Earlier, Sao Paulo's Butantan biomedical institute said it will seek approval ... Butantan aims to produce 40 million doses of the Butanvac vaccine ... The vaccine was developed using a modified virus, which causes the Newcastle disease in birds ...
sun-et-al-ndv-2020
was invoked but never defined (see the help page).struc-based-des-nature
was invoked but never defined (see the help page).